Government of Canada / Gouvernement du Canada
Symbol of the Government of Canada

Search

Food and Drug Regulations (C.R.C., c. 870)

Regulations are current to 2020-09-22 and last amended on 2020-07-01. Previous Versions

PART GControlled Drugs (continued)

DIVISION 1General (continued)

Application

Marginal note:Agricultural implants

  •  (1) The Act and this Part do not apply in respect of a controlled drug that is contained in an agricultural implant and set out in Part III of the schedule to this Part, but nothing in this section exempts such a drug from the requirements of Part C.

  • Marginal note:Definition of agricultural implant

    (2) In this section, agricultural implant means a product that is presented in a form suitable to allow sustained release of an active ingredient over a certain period of time and that is intended for insertion under the skin of a food-producing animal for the purpose of increasing weight gain and improving feed efficiency.

  • SOR/97-515, s. 3
  • SOR/99-125, s. 1
  • SOR/2003-34, s. 1
  • SOR/2003-413, s. 1
  • SOR/2018-69, ss. 67, 68
  • SOR/2019-171, s. 1

 [Repealed, SOR/2019-171, s. 1]

Marginal note:Member of police force

 A member of a police force or a person acting under their direction and control who, in respect of the conduct of the member or person, is exempt from the application of subsection 4(2) or section 5, 6 or 7 of the Act by virtue of the Controlled Drugs and Substances Act (Police Enforcement) Regulations is, in respect of that conduct, exempt from the application of this Part.

  • SOR/80-543, s. 11
  • SOR/2004-238, s. 2(F)
  • SOR/2019-171, s. 1

Marginal note:Application of Parts C and D

 Except as otherwise provided in this Part, it is prohibited to sell or provide a controlled drug or a preparation that does not comply with all provisions of Parts C and D that are applicable to it.

  • SOR/92-386, s. 2
  • SOR/97-228, s. 8
  • SOR/2019-171, s. 1

Possession

Marginal note:Authorized persons

  •  (1) A person is authorized to possess a controlled drug set out in any of items 1 to 3, 8 to 10, 12 to 14, 16 and 17 of Part I of the schedule to this Part if the person has obtained the controlled drug in accordance with these Regulations, in the course of activities conducted in connection with the administration or enforcement of an Act or regulation, or from a person who is exempt under section 56 of the Act from the application of subsection 5(1) of the Act with respect to that controlled drug, and the person

    • (a) requires the controlled drug for their business or profession and is

      • (i) a licensed dealer,

      • (ii) a pharmacist, or

      • (iii) a practitioner who is registered and entitled to practise in the province in which they possess that drug;

    • (b) is a practitioner who is registered and entitled to practise in a province other than the province in which they have that possession for emergency medical purposes only;

    • (c) is a hospital employee or a practitioner in a hospital;

    • (d) has obtained the controlled drug for their own use

      • (i) from a practitioner, or

      • (ii) in accordance with a prescription that was not issued or obtained in contravention of these Regulations;

    • (e) is a practitioner of medicine who received the controlled drug under subsection G.06.003(1) or (2) and their possession is for the purpose of providing or delivering it to a person referred to in subsection G.06.003(3);

    • (f) is an agent or mandatary of a practitioner of medicine who received the controlled drug under subsection G.06.003(1) and their possession is for the purpose of providing or delivering it to a person referred to in subsection G.06.003(2);

    • (g) is employed as an inspector, a member of the Royal Canadian Mounted Police, a police constable, a peace officer or a member of the technical or scientific staff of the Government of Canada, the government of a province or a university in Canada and their possession is in connection with that employment;

    • (h) is not a practitioner of medicine referred to in paragraph (e) or an agent or mandatary referred to in paragraph (f), is exempted under section 56 of the Act with respect to possession of that controlled drug and their possession is for a purpose set out in the exemption; or

    • (i) is the Minister.

  • Marginal note:Agent or mandatary

    (2) A person is authorized to possess a controlled drug referred to in subsection (1) if the person is acting as the agent or mandatary of any person who is authorized to possess it in accordance with any of paragraphs (1)(a) to (e), (h) and (i).

  • Marginal note:Agent or mandatary — person referred to in paragraph (1)(g)

    (3) A person is authorized to possess a controlled drug referred to in subsection (1) if they

    • (a) are acting as the agent or mandatary of a person who they have reasonable grounds to believe is a person referred to in paragraph (1)(g); and

    • (b) possess the controlled drug for the purpose of assisting that person in the administration or enforcement of an Act or a regulation.

  • SOR/2019-171, s. 1

Test Kits

Marginal note:Authorized activities

 A person may sell, possess or otherwise deal in a test kit if the following conditions are met:

  • (a) a registration number has been issued for the test kit under section G.01.008 and has not been cancelled under section G.01.009;

  • (b) the test kit bears, on its external surface,

    • (i) the name of the manufacturer,

    • (ii) the trade name or trademark, and

    • (iii) the registration number; and

  • (c) the test kit will be used for a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose.

  • SOR/2019-171, s. 1

Marginal note:Application for registration number

  •  (1) The manufacturer of a test kit may obtain a registration number for it by submitting to the Minister an application containing

    • (a) a detailed description of the design and construction of the test kit;

    • (b) a detailed description of the controlled drug and other substances, if any, contained in the test kit, including the qualitative and quantitative composition of each component; and

    • (c) a description of the proposed use of the test kit.

  • Marginal note:Signature and attestation

    (2) The application must

    • (a) be signed and dated by the person authorized by the applicant for that purpose; and

    • (b) include an attestation by that person that all of the information submitted in support of the application is correct and complete to the best of their knowledge.

  • Marginal note:Additional information or document

    (3) The applicant must, not later than the date specified in the Minister’s written request to that effect, provide the Minister with any information or document that the Minister determines is necessary to complete the review of the application.

  • SOR/2019-171, s. 1

Marginal note:Issuance of registration number

 On completion of the review of the application for a registration number, the Minister must issue a registration number for the test kit, preceded by the letters “TK”, if the Minister determines that the test kit will only be used for a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose and that it contains

  • (a) a controlled drug and an adulterating or denaturing agent that are combined in such a manner and in such a quantity, proportion or concentration that the preparation or mixture has no significant drug abuse potential; or

  • (b) such small quantities or concentrations of any controlled drug as to have no significant drug abuse potential.

  • SOR/2019-171, s. 1

Marginal note:Cancellation of registration number

 The Minister must cancel the registration number for a test kit if

  • (a) the test kit is removed from the market by the manufacturer;

  • (b) the Minister has reasonable grounds to believe that the test kit is used or is likely to be used for any purpose other than a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose; or

  • (c) the Minister has reasonable grounds to believe that the cancellation is necessary to protect public health or safety, including to prevent a controlled drug from being diverted to an illicit market or use.

  • SOR/2019-171, s. 1
 
Date modified: